Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309167 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL850609 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL879887 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL5619569 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL4229986 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL580258 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL7564811 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL517888 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL31490075 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL581027 | 0.98 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361248-A1 | PROTAC COMPOUND WITH CYCLOPHILIN A DEGRADATION ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2025-11-27 | — | — | US | claimed |
| WO-2024031965-A1 | PROTAC COMPOUND WITH CYCLOPHILIN A DEGRADATION ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳湾实验室 | 2024-02-15 | — | — | WO | claimed |
| CN-115028679-B | PROTAC compound with Cyclophilin A degradation activity and preparation method and application thereof | 深圳湾实验室 | 2022-11-15 | — | — | CN | claimed |
| CN-115028679-A | PROTAC compound with Cyclophilin A degradation activity and preparation method and application thereof | 深圳湾实验室 | 2022-09-09 | — | — | CN | claimed |
| CN-110642682-A | Synthesis method of 5-oxaazelaic acid | 上海吉奉生物科技有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-20180194713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2018-07-12 | — | — | US | claimed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4658636-A1 | LIPID COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | PFIZER (US) | 2025-12-04 | — | — | US | disclosed |
| US-4777184-A | ANTICOAGULANT, ANTIULCER AGENT | SANKYO COMPANY LIMITED (JP) | 1988-10-11 | — | — | US | disclosed |
| EP-0215401-A2 | Method and composition for determining glycosylated hemoglobin as well as compounds suited therefor and methods for their preparation | Roche Diagnostics GmbH (DE) | 1987-03-25 | — | — | EP | disclosed |
| US-4649219-A | CROSSLINKERS, ADHESIVES, PAINTS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1987-03-10 | — | — | US | disclosed |
| US-4426526-A | HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY, ANTISECRETORY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-01-17 | — | — | US | disclosed |
| US-4264608-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-04-28 | — | — | US | disclosed |
| US-4156727-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-29 | — | — | US | disclosed |
| US-4154838-A | ANTIHISTAMINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | TSHR 3661/4885TDP1 3260/4885L3MBTL1 4881/4885 |
| US-20250361248-A1 | PROTAC COMPOUND WITH CYCLOPHILIN A DEGRADATION ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | PPIA, PPIG, PPIF | TSHR 4333/4885TDP1 3463/4885L3MBTL1 4638/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | TSHR 1630/4885TDP1 2586/4885L3MBTL1 666/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | TSHR 3129/4885TDP1 2093/4885L3MBTL1 1235/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | TSHR 1673/4885TDP1 1739/4885L3MBTL1 317/4885 |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | POLN, PHOSPHO1, NPC1 | TSHR 3471/4885TDP1 1138/4885L3MBTL1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.